XELOX vs FOLFOX-4 as first-line therapy for metastatic colorectal cancer: NO16966 updated results. (Q34630237)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21673685 AND SRC:MED&resulttype=core&format=json

4 February 2020

title

XELOX vs FOLFOX-4 as first-line therapy for metastatic colorectal cancer: NO16966 updated results (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21673685 AND SRC:MED&resulttype=core&format=json

4 February 2020

1 reference

metastatic colon cancer

1 reference

1 reference

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21673685 AND SRC:MED&resulttype=core&format=json

4 February 2020

Leonard B. Saltz

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21673685 AND SRC:MED&resulttype=core&format=json

4 February 2020

author name string

J Cassidy

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21673685 AND SRC:MED&resulttype=core&format=json

4 February 2020

S Clarke

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21673685 AND SRC:MED&resulttype=core&format=json

4 February 2020

W Scheithauer

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21673685 AND SRC:MED&resulttype=core&format=json

4 February 2020

A Figer

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21673685 AND SRC:MED&resulttype=core&format=json

4 February 2020

R Wong

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21673685 AND SRC:MED&resulttype=core&format=json

4 February 2020

S Koski

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21673685 AND SRC:MED&resulttype=core&format=json

4 February 2020

K Rittweger

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21673685 AND SRC:MED&resulttype=core&format=json

4 February 2020

F Gilberg

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21673685 AND SRC:MED&resulttype=core&format=json

4 February 2020

language of work or name

English

0 references

publication date

14 June 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21673685 AND SRC:MED&resulttype=core&format=json

British Journal of Cancer

4 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21673685 AND SRC:MED&resulttype=core&format=json

4 February 2020

volume

105

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21673685 AND SRC:MED&resulttype=core&format=json

4 February 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21673685 AND SRC:MED&resulttype=core&format=json

4 February 2020

page(s)

58-64

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21673685 AND SRC:MED&resulttype=core&format=json

Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/leucovorin plus oxaliplatin (FOLFOX-6) as first-line treatment for metastatic colorectal cancer

4 February 2020

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3137415

Efficacy of oxaliplatin plus capecitabine or infusional fluorouracil/leucovorin in patients with metastatic colorectal cancer: a pooled analysis of randomized trials

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3137415

Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3137415

Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3137415

Capecitabine as adjuvant treatment for stage III colon cancer

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3137415

Is overall survival a realistic primary end point in advanced colorectal cancer studies? A critical assessment based on four clinical trials comparing fluorouracil plus leucovorin with the same treatment combined either with oxaliplatin or with CPT-

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3137415

Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3137415

Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3137415

Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3137415

Costs associated with complications are lower with capecitabine than with 5-fluorouracil in patients with colorectal cancer

7 July 2018

1 reference

https://api.crossref.org/works/10.1038/BJC.2011.201

Randomised trial comparing biweekly oxaliplatin plus oral capecitabine versus oxaliplatin plus i.v. bolus fluorouracil/leucovorin in metastatic colorectal cancer patients: results of the Southern Italy Cooperative Oncology study 0401.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/BJC.2011.201

Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX-4) as second-line therapy in metastatic colorectal cancer: a randomized phase III noninferiority study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/BJC.2011.201

Phase III Study of Capecitabine Plus Oxaliplatin Compared With Continuous-Infusion Fluorouracil Plus Oxaliplatin As First-Line Therapy in Metastatic Colorectal Cancer: Final Report of the Spanish Cooperative Group for the Treatment of Digestive Tumor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/BJC.2011.201

Phase III study of capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin in metastatic colorectal cancer: a final report of the AIO Colorectal Study Group

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21673685

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1038/BJC.2011.201

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21673685 AND SRC:MED&resulttype=core&format=json

Dimensions Publication ID

4 February 2020

0 references

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21673685 AND SRC:MED&resulttype=core&format=json

4 February 2020

PubMed publication ID

21673685

1 reference